Neurology News with information about conditions, treatments, current studies and breakthroughs.
15 Minute Workout
Take a look at the video below for a quick 15 minute workout that can be done on a daily [...]
Why Exercise Promotes Better Sleep
Many people struggle with getting a good night's sleep. Studies have shown that regular exercise can improve sleep quality, and [...]
Spending Time in Nature Can Slow Parkinson’s and Alzheimer’s
Living in areas with easy access to parks and nature appears to slow down the progression of neurological diseases like [...]
Neuroscientist Wins $2.5 Million Grant to Treat Substance Abuse Disorder
Travis Baker recently won a $2.5 million grant from the National Institute of Drug Abuse (NIDA) to treat substance abuse [...]
Depression Questionnaire
The PHQ-9 test is one of several diagnostic tools that can be used in the screening of depression. It can [...]
Generalized Anxiety Disorder Self Assessment
The GAD-7 is a screening tool used by medical professionals for generalized anxiety disorder. It also can show the severity [...]
- Exposure to Air Pollutants and Lewy Body and Parkinson Disease–Related Dementias June 12, 2026New JAMA Publication! Congratulations to Dimitry S. Davydow, MD, MPH, Gregory M. Pontone, MD, MHS, Michael S. Okun, MD, and Melissa J. Armstrong, MD on their publication “Exposure to Air Pollutants and Lewy Body and Parkinson Disease–Related Dementias,” which appears in JAMA Open Network. Long-term exposure to common air pollutants may increase the risk of developing Parkinson’s disease-related dementia and Lewy body dementia, according to…
- Real-World Safety and Effectiveness of 24-Hour Foslevodopa/Foscarbidopa in Parkinson’s Disease: ROSSINI Study 6-Month Interim Results June 10, 2026Congratulations Dr. Irene Malaty Dr. Malaty research “Real-World Safety and Effectiveness of 24-Hour Foslevodopa/Foscarbidopa in Parkinson’s Disease: ROSSINI Study 6-Month Interim Results,” was published in the May 2026 issue of Neurology and Therapy. Abstract Foslevodopa/foscarbidopa (LDp/CDp) is a nonsurgical 24-h continuous subcutaneous infusion for patients with advanced Parkinson’s disease (aPD) and motor fluctuations uncontrolled on…
- Diffusion MRI and α‐Synuclein Seed Amplification Status in Parkinson’s Disease June 8, 2026New Publication! Congratulations to Drs. Melissa J Armstrong, Nikolaus R. McFarland, Michael Okun and David Vaillancourt on the publication of “Diffusion MRI and α‐Synuclein Seed Amplification Status in Parkinson’s Disease,” which appears in the May edition of Annals of Neurology. Abstract Objective Positive α‐synuclein seed amplification assay (SAA) is a biomarker found in most people…
- Unveiling Reporting & Representation of Race and Ethnicity in Acute Interventional Neurology Trials: A Systematic Review June 5, 2026Congratulations on your new publication! Congratulations to Hector David Meza Comparan, Luciola Frota, Michael Mathelier, Carolina Maciel and Katharina Busl on the publication of “Unveiling Reporting & Representation of Race and Ethnicity in Acute Interventional Neurology Trials: A Systematic Review,” which appears in the April 8th edition of Neurology. Abstract Objective: To evaluate the extent and…
Get Social